Introducing the pneumococcal conjugate vaccine in India's National Immunization Programme: an economic-epidemiological analysis using agent-based modelling

Research output: Contribution to conferenceAbstractpeer-review

Abstract

Pneumococcal pneumonia causes over 100,000 child deaths in India annually. Uncertainty regarding the impact of introducing the pneumococcal conjugate vaccine and its high cost have been a concern, particularly after the proposed GAVI alliance support ends. We evaluate disease transmission and the vaccine’s disease and economic impact in an agent-based simulation model representative of the Indian population and healthcare system. Despite its high cost, introducing the vaccine averts a significant number of deaths and protects poor populations from financial risk.
Original languageEnglish
Number of pages1
Publication statusPublished - 28 Jul 2017
EventINFORMS Healthcare 2017 - Rotterdam, Netherlands
Duration: 26 Jul 201728 Jul 2017
http://meetings2.informs.org/wordpress/healthcare2017/

Conference

ConferenceINFORMS Healthcare 2017
Country/TerritoryNetherlands
CityRotterdam
Period26/07/1728/07/17
Internet address

Keywords

  • india
  • national immunization programme

Fingerprint

Dive into the research topics of 'Introducing the pneumococcal conjugate vaccine in India's National Immunization Programme: an economic-epidemiological analysis using agent-based modelling'. Together they form a unique fingerprint.

Cite this